Jesy Nelson, the former Little Mix singer, has achieved a significant victory in her campaign for newborn screening after her twin daughters were diagnosed with spinal muscular atrophy (SMA) too late. On April 1, 2026, the Mirror reported that Health Secretary Wes Streeting has accelerated plans for the NHS in England to begin testing hundreds of thousands of newborns for this devastating muscle-wasting disease. The move comes as a direct response to Jesy’s advocacy, highlighting how early diagnosis could prevent irreversible damage for countless babies.

Jesy Nelson’s twins, Ocean Jade and Story Monroe, were born prematurely and diagnosed with SMA Type 1 in January 2026. By the time doctors identified the condition, irreversible nerve damage had already occurred. Medical professionals informed Jesy that her daughters would never walk due to the delayed treatment. This heartbreaking reality propelled the 34-year-old singer into action. Alongside her partner, Zion Foster, Jesy has shared their family’s journey publicly, using her platform to raise awareness and demand change.

Spinal muscular atrophy is a rare genetic disorder caused by a fault in the SMN1 gene. This gene is responsible for producing SMN protein, which keeps motor neurons healthy. These neurons transmit signals from the brain and spinal cord to the muscles. Without sufficient SMN protein, the motor neurons die off, leading to progressive muscle weakness and wasting, particularly affecting the legs, arms, and chest. In its most severe form, SMA Type 1, symptoms often appear in early infancy, including reduced movement, feeding difficulties, and breathing problems. Without intervention, the condition can be life-limiting.

The good news is that groundbreaking treatments now exist and are available on the NHS. These include Nusinersen (Spinraza), an injection administered every four months around the spine to boost SMN protein production; Evrysdi, a daily oral liquid; and Zolgensma, a one-time gene therapy infusion that delivers a healthy copy of the SMN1 gene. When given at birth or very early, these therapies can effectively halt or even prevent the disease’s progression, offering outcomes close to a cure. However, once nerve damage sets in—as happened with Jesy’s twins—the treatments cannot reverse existing disabilities.

For years, the Mirror newspaper has campaigned for SMA to be added to the routine newborn blood spot test, commonly known as the heel prick test. This simple procedure, performed when babies are around five days old, currently screens for just 10 serious conditions in the UK by collecting a few drops of blood from the heel. Many countries screen for far more—Italy checks for 48, while the United States and nearly three-quarters of European nations, including Poland and even Ukraine amid conflict, include SMA. The UK has lagged behind despite accumulating global evidence showing the benefits of early detection.

Jesy Nelson joined forces with the Mirror and SMA UK, the leading charity supporting those affected by the condition. In February 2026, she launched a petition calling for SMA screening to be included in the heel prick test. The petition gained over 100,000 signatures in a single day, moving Jesy to tears as she realized the scale of public support. She met with Health Secretary Wes Streeting and Giles Lomax, chief executive of SMA UK, to share her personal experiences and push for faster action.

In an exclusive letter to Jesy and Giles Lomax, Streeting confirmed progress. An NHS pilot program, known as the In-Service Evaluation (ISE), for SMA screening had been delayed for years and was originally slated to begin in January 2027. Thanks to intervention, it will now launch in October 2026—three months earlier—and cover an estimated 404,000 babies in England. This represents a major step forward, though not a full national rollout yet. Around 163,000 newborns will still not be tested to serve as a control group for comparison, a decision some experts have criticized as unethical, potentially leaving about 11 babies a year diagnosed too late.

Scotland has already committed to screening all newborns for SMA starting in early 2026, making it the first UK nation to do so. Decisions are still pending in Wales and Northern Ireland, where thousands of babies will remain untested annually. Streeting expressed his desire for a complete rollout across England, stating he would continue working through logistical challenges and keep Jesy and the charity updated.

Jesy has described the announcement as “amazing,” bringing hope not only to her family but to future parents. She has spoken emotionally about the guilt and frustration of learning too late what could have been prevented with a simple £5 blood test at birth. Her twins’ diagnosis came after months of appointments, initially attributed to prematurity. Reduced leg movement and feeding struggles were early red flags that might have been caught immediately through screening.

The campaign underscores broader issues with the UK’s newborn screening program. While effective for the conditions it covers, it screens for far fewer disorders than many comparable nations. Advocates argue that with treatments now available, delaying SMA screening costs babies their mobility, independence, and in severe cases, their lives. Medics treating SMA patients have questioned why further studies were needed when international data already demonstrates clear benefits.

For Jesy Nelson, this partial victory is bittersweet. Her daughters, now receiving treatment, face lifelong challenges, but she remains determined to ensure no other family endures the same preventable heartache. Her openness has humanized the issue, turning a medical policy debate into a deeply personal story that resonates with parents nationwide.

This development also highlights the power of celebrity advocacy combined with media campaigns. The Mirror’s long-running push, amplified by Jesy’s voice and the petition’s success, directly influenced government timelines. It serves as a reminder that public pressure can accelerate health policy changes.

As the pilot begins in October 2026, families across England will benefit from earlier interventions. Jesy continues to call for full implementation without delay, urging officials to expand the program nationwide as soon as possible. Her message is clear: every moment matters for babies with SMA, and early testing can transform futures.

In the meantime, Jesy balances motherhood with advocacy, sharing glimpses of life with her twins while pushing for systemic change. Her story illustrates both the devastating impact of late diagnosis and the hope that comes from timely treatment. With treatments that can stop SMA in its tracks when caught early, the case for universal screening grows stronger every day.

The NHS pilot marks meaningful progress, but campaigners like Jesy Nelson and SMA UK will not stop until every newborn in the UK receives the protection of this life-changing test. For thousands of families, that simple heel prick could mean the difference between a lifetime of disability and the chance to thrive.